FDA Approves Oral Semaglutide for Cardiovascular Risk Reduction in Type 2 Diabetes
- 23 October 2025
- 1 week ago
EMA Committee approves update to Novo Nordisk Rybelsus label to reflect cardiovascular benefits
- 18 September 2025
- 1 month ago
Novo Nordisk Gets CDSCO Panel Nod for Rybelsus Label Update, Aligned with EMA
- 10 September 2025
- 1 month ago
Recent News
Himachal notifies Resident doctor policy 2025
- 02 November, 2025
Pfizer files lawsuit against Metsera, its Director...
- 02 November, 2025
Health Ministry achieves 3 Guinness World Records...
- 02 November, 2025
Roche gets CE mark for Elecsys Dengue Ag test to d...
- 02 November, 2025
Daily Newsletter
Get all the top stories from Blogs to keep track.



